Alerta

异源抗原诱导免疫共振以重编免疫系统功能的方法

Resumen de: CN121648320A

本发明提供异源抗原诱导免疫共振以重编免疫系统功能的方法，属于免疫学和肿瘤学技术领域；S1、筛选针对目标肿瘤/癌症细胞的特异性异源抗原；S2、对筛选得到的异源抗原进行修饰处理，以克服肿瘤/癌症的免疫逃逸或/和增强其免疫原性、改变其靶向性，修饰方式包括但不限于与载体结合、进行化学修饰、添加佐剂等；S3、将修饰后的异源抗原递送至宿主的肿瘤/癌症病原体部位或其微环境中；S4、监测宿主免疫系统对异源抗原的响应，以及肿瘤/癌症病原体的变化情况，根据监测结果调整异源抗原的剂量、施药频率和施药方式。本发明通过筛选特异性异源抗原并进行修饰处理，增强了其免疫原性和靶向性，同时评估保障了治疗的安全性。

miR-99b和SIRPα siRNA在制备治疗肝细胞癌的药物中的应用

Resumen de: CN121648077A

本发明公开了包含miR‑99b和SIRPα siRNA的药物组合物在制备用于治疗肝细胞癌及逆转其肿瘤免疫抑制微环境的药物中的应用。所述药物组合物通过将两种核酸药物共同递送至肿瘤相关巨噬细胞，协同发挥将M2型巨噬细胞重编程为M1型以及下调SIRPα蛋白以阻断CD47‑SIRPα“别吃我”信号通路的双重作用，从而增强巨噬细胞吞噬功能、抑制肿瘤生长与转移、促进T细胞浸润，最终有效逆转免疫抑制并激活抗肿瘤免疫应答，所述药物组合物通过经甘露糖修饰且含有二硫键PEG化脂质的脂质纳米粒子实现靶向共递送。

脂质纳米颗粒制剂和组合物

Resumen de: AU2024279278A1

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

一种负载二乙基二硫代氨基甲酸锰的纳米颗粒以及药物组合物

Resumen de: CN121648080A

本申请属于生物医药与肿瘤诊疗技术领域，具体涉及一种负载二乙基二硫代氨基甲酸锰的纳米颗粒以及药物组合物。所述负载二乙基二硫代氨基甲酸锰的纳米颗粒包括质量比为(0.25~4):1的两亲性聚合物以及二乙基二硫代氨基甲酸盐；二乙基二硫代氨基甲酸锰占所述二乙基二硫代氨基甲酸盐的摩尔质量的50%以上；所述两亲性聚合物为DSPE‑PEG、DSPE‑PEG‑叶酸、DSPE‑PEG‑苯硼酸，DSPE‑PEG‑精氨酰甘氨酰天冬氨酸肽中的一种或多种。本申请采用DSPE‑PEG及其衍生物的两亲性聚合物与乙基二硫代氨基甲酸盐形成纳米颗粒，可以将疏水性的乙基二硫代氨基甲酸锰包裹在疏水微区。

一种高负载姜黄素-壳聚糖纳米颗粒及其制备方法和应用

Resumen de: CN121648079A

本发明公开了一种高负载姜黄素‑壳聚糖纳米颗粒及其制备方法和应用，属于生物材料领域。其技术方案包括由壳聚糖包裹姜黄素形成纳米颗粒，姜黄素与壳聚糖的质量比为5:1～1:5；制备方法步骤包括：制备pH=11.0～13.0的姜黄素水溶液；制备pH=1.4～2.8的壳聚糖水溶液；将姜黄素水溶液滴加至壳聚糖溶液中，得到混合液；滴加速率为0.8～1.2mL/min。本发明还公开了一种上述方法制备的高负载姜黄素‑壳聚糖纳米颗粒及使用上述纳米颗粒包裹益生菌的应用。本发明所要解决的技术问题是现有技术无法实现姜黄素与益生菌共同投递、稳定储存、在胃酸环境中稳定、在肠道精准释放等要求的问题。

用于制备环状RNA的内含子剪切系统和DNA载体

Resumen de: CN121653184A

本发明属于生物技术领域，具体涉及用于制备环状RNA的内含子剪切系统和DNA载体。本发明筛选出一种噬菌体高效自剪切内含子系统，其环化效率远优于其他内含子，且无需外源酶即可自剪切环化，克服了传统方法副产物多的缺陷。同时，基于此构建含内含子双臂的模块化DNA载体，可灵活插入目标序列，前体RNA转录后直接成环，无需复杂修饰，简化流程且通用性强。此外，成环后的RNA抗降解，经LNP包载后细胞转染效率92.12%、GFP信号为1×105，显著高于线性RNA（62.63%、2×104），为核酸药物研发提供核心支撑；流程标准化可控，常规纯化即可质控，便于规模化生产。

一种用于结肠靶向递送的载药微藻马达系统及其制备方法与应用

Resumen de: CN121648074A

本发明公开了一种用于结肠靶向递送的载药微藻马达系统及其制备方法与应用。所述载药微藻马达系统包括莱茵衣藻微藻马达核心，其表面通过静电吸附作用氨基化四氧化三铁纳米颗粒，包裹槲皮素修饰的壳聚糖季铵盐，形成具有磁响应性的纳米复合体，并被封装于海藻酸钠微球中。本发明利用莱茵衣藻作为辅助治疗的抗氧化剂，在结肠环境中，海藻酸钠微球可响应特定条件降解，释放出微藻马达在肠液中自主运动，并在外部磁场引导下，精准靶向肠道病灶部位。本发明兼具良好的生物相容性、生物可降解性、胃酸规避能力以及磁/化学双重驱动靶向功能，能有效提高对结肠疾病的治疗效果，并显著降低药物的全身性副作用，拓展了微纳米马达在生物医学领域的应用。

可离子化脂质化合物的用途及分离的免疫细胞

Resumen de: CN121648078A

本申请提供了可离子化脂质化合物的用途及分离的免疫细胞。具体地，本申请提供了可离子化脂质化合物、其药学上可接受的盐或立体异构体用于向免疫细胞中递送核酸的用途，其中可离子化脂质化合物如式（I）所示：（I）其中，R1、R2各自独立地为C2‑10亚烷基，L1、L2各自独立地为‑O(C=O)‑、‑(C=O)O‑或‑NH(C=O)‑，R3为对位烷氧基取代的苯基或间位二烷氧基取代的苯基，其中所述烷氧基为C2‑20烷氧基，R4为C10‑19支化烷基，并且R5、R6各自独立地为C2‑6亚烷基。本发明特定的可离子化脂质化合物可以显著提高对T细胞的转染效率，这极大地助力于CAR‑T疗法的成功和有效性。

正交近红外光驱动成像/膜靶向光动力治疗探针及其方法

Resumen de: CN121648289A

本发明涉及肿瘤诊疗探针的制备与应用技术领域，且公开了一种正交近红外光驱动成像/膜靶向光动力治疗探针及其方法，通过溶胶凝胶法，将掺杂光敏剂脱镁叶绿酸盐A和全氟化碳的介孔硅修饰到稀土下转换纳米粒子表面；将介孔硅修饰的下转换纳米粒子与二硬脂酰基磷脂酰乙醇胺‑PEG混合，最终得到正交近红外光驱动成像/膜靶向光动力治疗探针。本发明中制备的纳米探针可在980nm与808nm激光下分别实现正交近红外光驱动成像与光动力治疗，构成合理的正交近红外光激发体系，同时在溶液、细胞及活体水平实验中表明，该纳米探针生物相容性良好，并能通过膜靶向光动力疗法高效诱导细胞焦亡，在体外和体内均展现出优异的治疗性能。

一种基于乳清蛋白纳米微囊包埋技术的中药苦味屏蔽方法及其应用

Resumen de: CN121648076A

本发明公开了一种基于乳清蛋白纳米微囊包埋技术的中药苦味屏蔽方法及其应用，乳清蛋白纳米微囊包埋过程中准备中药材、壁材、溶剂、乳化剂、风味油脂、高压微胶囊包埋机、超声波乳化器、真空干燥箱、电子天平、pH计、离心机、煎药锅、滤纸、容量瓶、无味无毒容器，制备黄芪提取液、车前子提取液以及双黄连提取液，配制壁材溶液，确定乳化剂的用量，将这些材料混合乳化并制备微囊，最终将微囊进行包裹、固化，制备样品，采用光学显微镜对稳定乳液进行观察，该乳清蛋白纳米微囊包埋技术，采用食品级乳清蛋白与药材按照比例制备成稳定的纳米微囊，采用两次包裹，对药物具有良好的包裹效果，有效隔绝药物本身的苦涩，纳米微囊对活性成分的包封率很高。

一种类脂质分子、其组合物及应用

Resumen de: CN121652088A

本发明涉及一种类脂质分子、其组合物及应用。本发明的类脂质分子核心结构涵盖二维平面结构及多种三维立体结构，赋予LNP可调控的膜组织特性和胞内转运行为，实现了从结构层面调节递送性能的新策略。此外，部分可电离脂质引入氟取代基团，提高LNP内部疏水相互作用与胶体稳定性，延长体内递送持续性。本发明还提出了一种基于可电离脂质化学键可编程调控的组分精简型LNP递送体系，与传统认为需去除肝嗜性组分（如胆固醇）或额外引入靶向调控脂质（第五组分）以实现器官靶向的策略不同，本发明发现，仅通过改变可电离脂质中脂肪链与核心结构之间的化学键类型，即可在保留胆固醇的条件下实现对肝、脾、肺、胰腺等器官的选择性递送。

一种花蟹功能肽、花蟹功能肽包埋体及其制备方法和应用

Resumen de: CN121652223A

本发明公开了一种花蟹功能肽包埋体及其制备方法和应用，特点是花蟹功能的肽氨基酸序列为TDVC，其中制备方法包括以下步骤：1）将花蟹肉搅碎溶于去离子水中加入中性蛋白酶酶解后，用截留分子量为5kDa的膜进行超滤，取截留液得到花蟹肽粗提物；2）将花蟹肽粗提物采用Sephadex G‑25层析柱用超纯水进行洗脱，收集各洗脱峰，筛选出抗氧化能力最强的洗脱组分进行Sephadex G‑15层析柱分离，以超纯水为洗脱液，收集各洗脱峰，筛选出抗氧化能力最强的洗脱组分后，进行浓缩干燥后得到花蟹功能肽，优点是具有抗氧化/抗炎双功能、具有显著的肠道靶向释放效果，且能提高消化后TDVC的细胞抗氧化/抗炎活性。

一种靶向骨关节炎H型新生血管的多肽、纳米探针及应用

Resumen de: CN121652293A

本发明属于生物医药技术领域，提供了一种靶向骨关节炎H型新生血管的多肽、纳米探针及应用，所述多肽的氨基酸序列如SEQ ID NO：1所示。本发明提供的多肽及纳米探针可以特异性识别H型新生血管，并克服骨组织递送屏障，为调控骨骼‑血管微环境相互作用开辟新的途径，具有重要的科学意义与临床转化价值。

COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES

Resumen de: US20260069677A1

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

LIPIDIC PARTICLES CONTAINING IONISABLE LIPIDS FOR EXTRAHEPATIC DELIVERY

Resumen de: WO2026052732A1

It is provided a lipid particle comprising an ionisable lipid, a neutral helper lipid, a stealth lipid or a pharmaceutically acceptable salt or stereoisomer or tautomer or isotopic variant of any one of them, for use as an encapsulation agent, optionally comprising a cargo molecule or a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid particle. It is also provided a lipid particle or a pharmaceutical composition comprising thereof for use in medicine, and the use of the lipid particle as an encapsulating agent for extrahepatic targeting.

METHODS FOR PURIFICATION OF IONIZABLE LIPIDS

Resumen de: US20260069712A1

Provided herein are methods for purifying an ionizable amino lipid (IAL) composition comprising impurities that may react with polynucleotides, such as mRNA. Methods for purifying IAL compositions comprise one or more scavenging-removal steps to selectively remove reactive impurities.

SYSTEMS, DEVICES AND METHODS FOR MODULAR FUNCTIONALIZED CELLULAR NANOSTRUCTURES FOR TARGETED PAYLOAD DELIVERY

Resumen de: US20260069711A1

Disclosed are devices, systems, and methods of manufacture and use of modular functionalized cellular nanoparticles that can bind a wide range of ligands, payloads, and functional substances onto a nanoparticle surface. In various embodiments, a cell membrane coating on the nanoparticle is engineered to express a membrane anchor that can readily form a covalent bond with any functional moiety modified with an appropriate peptide tag sequence.

LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES

Resumen de: US20260069714A1

Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.

LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF

Resumen de: US20260069710A1

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF

Resumen de: US20260069684A1

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

NUCLEIC ACID VACCINES ENCAPSULATED WITH NANOALUMINOSILICATE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV)

Resumen de: US20260069675A1

A MERS-CoV vaccine with nucleic acid sequences having at least 90% identity to the spike gene of a MERS-CoV strain as a preventive measure against MERS-CoV infections is described. The nucleic acid sequences may include plasmid DNA (pDNA) or messenger RNA (mRNA) that are encapsulated by aluminosilicates. The aluminosilicates may be functionalized with aminopropyltrimethoxysilanes.

CORONAVIRUS SPIKE PROTEIN-BASED VACCINES

Resumen de: US20260069679A1

Described herein are polypeptides and nanoparticles that display polypeptide sequences, e.g., spike protein domains. In some embodiments, the polypeptides and/or nanoparticles can be used to raise or stimulate an immune response, e.g., as a vaccine.

ORAL VACCINE FOR ENHANCING CANCER IMMUNOTHERAPY

Resumen de: US20260069669A1

The disclosure provides an oral vaccine for enhancing cancer immunotherapy, which includes a complex of β-glucan and mRNA and lipid nanoparticles, wherein the mRNA includes a coding region of a tumor antigen, and the lipid nanoparticles encapsulate the complex of β-glucan and mRNA.

ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF

Resumen de: US20260069698A1

The present invention provides prodrugs and methods of use thereof.

COMPOSITIONS AND METHODS FOR TREATING VENOUS BLOOD CLOTS

Nº publicación: US20260069664A1 12/03/2026

Solicitante:

THE UNIV OF NORTH CAROLINA AT CHAPEL HILL [US]
NEW YORK UNIV [US]
The University of North Carolina at Chapel Hill,
NEW YORK UNIVERSITY

Resumen de: US20260069664A1

Therapeutic compositions for treating a subject, the compositions including a polymeric nanoparticle, an active agent encapsulated within the polymeric nanoparticle, and a delivery vehicle for targeted delivery of the polymeric nanoparticle and encapsulated agent to a target tissue in the subject. The therapeutic compositions can be designed for targeting the destruction of a Nuclei neutrophil extracellular trap (NET) in a venous thrombus in a subject. The active agent can be an enzyme, including deoxyribonuclease 1 (DNase 1) enzyme. Methods of treating a subject using the therapeutic compositions are provided, including methods of treating venous thrombus, deep vein thrombosis, or a related blood clotting disease and/or condition.